Leftagraph

Every financial statement,
one clean chart.

Search any US-listed company. Data straight from SEC filings.

PROBuild your own list with the screener

Amylyx Pharmaceuticals, Inc. (AMLX) financial statements

Number look wrong? Tell us

Data table
PROBuild your own list with the screener

Amylyx Pharmaceuticals, Inc. (AMLX), most recent 12 months reported: revenue $0, net loss $152.09M, free cash flow -$123.48M. Latest balance sheet on file: liquid cash $250.76M. From SEC filings. Others in Pharmaceutical Preparations: Akari Therapeutics, Plc · ALDEYRA THERAPEUTICS, INC. · ALX ONCOLOGY HOLDINGS INC · ALZAMEND NEURO, INC. · ANEBULO PHARMACEUTICALS, INC. · ANIXA BIOSCIENCES, INC. · ANNEXON, INC. · Alto Neuroscience, Inc.

Stock screener

Watchlist